Rigel Pharmaceuticals, Inc. reported $277M of revenue over the trailing twelve months, +3.3% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $277M (to Q2 2026). Net income: $322M, trailing twelve months to Q2 2026. Operating margin: 31%, trailing twelve months to Q2 2026. EPS: $16.88, trailing twelve months to Q2 2026.

RIGLRigel Pharmaceuticals, Inc.

Healthcare

$48.76+65% 1Y

$48.76

$25.4452 weeks$50.96

RIGL as reported

Rigel Pharmaceuticals, Inc. reported $277M of revenue over the trailing twelve months, +3.3% on the year before. 11 reported series are charted on this page, each one as filed.

$277M

Revenue, trailing twelve months · to Q2 2026 · +3.3% against the twelve months before

Net income: $322M
Net income · +229% year on year · trailing twelve months to Q2 2026
Operating margin: 31%
Operating margin · trailing twelve months to Q2 2026
EPS: $16.88
EPS · +211% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RIGL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$277M	+3.3%	Q2 2026
Net income	$322M	+229%	Q2 2026
EPS	$16.88	+211%	Q2 2026
Gross margin	91%	n/a	Q2 2026
Operating margin	31%	n/a	Q2 2026
Net margin	115%	n/a	Q2 2026
ROE	89%	n/a	Q2 2026
ROA	63%	n/a	Q2 2026
ROIC	80%	n/a	Q2 2026
Free cash flow	−$74M	n/a	Q4 2022 · 14 quarters behind
P/E	2.89	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.